Background and aims-Assessing the presence and degree of intestinal inflamm
ation objectively, simply, and reliably is a significant problem in gastroe
nterology. We assessed faecal excretion of calprotectin, a stable neutrophi
l specific marker, as an index of intestinal inflammation and its potential
use as a screening test to discriminate between patients with Crohn's dise
ase and those with irritable bowel syndrome.
Methods-The validity of faecal calprotectin as a marker of intestinal infla
mmation was assessed in 22 patients with Crohn's disease (35 studies) by co
mparing faecal excretions and concentrations using four day faecal excretio
n of (111)indium white cells. A cross sectional study assessed the sensitiv
ity of faecal calprotectin concentration for the detection of established C
rohn's disease (n=116). A prospective study assessed the value of faecal ca
lprotectin in discriminating between patients with Crohn's disease and irri
table bowel syndrome in 220 patients referred to a gastroenterology clinic.
Results-Four day faecal excretion of (111)indium (median 8.7%; 95% confiden
ce interval (CI) 7-17%; normal <1.0%) correlated significantly (p<0.0001) w
ith daily (median ranged from 39 to 47 mg; normal <3 mg; r=0.76-0.82) and f
our day faecal calprotectin excretion (median 101 mg; 95% CI 45-168 mg; nor
mal <11 mg; r=0.80) and single stool calprotectin concentrations (median 11
8 mg/l; 95% CI 36-175 mg/l; normal <10 mg/l; r=0.70) in patients with Crohn
's disease. The cross sectional study showed a sensitivity of 96% for calpr
otectin in discriminating between normal subjects (2 mg/l; 95% CI 2-3 mg/l)
and those with Crohn's disease (91 mg/l; 95% CI 59-105 mg/l). With a cut o
ff point of 30 mg/l faecal calprotectin has 100% sensitivity and 97% specif
icity in discriminating between active Crohn's disease and irritable bowel
syndrome.
Conclusion-The calprotectin method may be a useful adjuvant for discriminat
ing between patients with Crohn's disease and irritable bowel syndrome.